Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Symbol: 002693.SZ
SHZ
5.18
CNYDzisiejsza cena rynkowa
2322.2660
Wskaźnik P/E
-133.5303
Wskaźnik PEG
2.14B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 512.21 | 146 | 77 | 100 | ||||||||||||||
balance-sheet.row.short-term-investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.net-receivables | 144.81 | 41 | 33.1 | 44.6 | ||||||||||||||
balance-sheet.row.inventory | 291.75 | 65.4 | 55.2 | 52.8 | ||||||||||||||
balance-sheet.row.other-current-assets | 0.05 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.total-current-assets | 948.81 | 252.4 | 165.4 | 197.5 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1849.45 | 471.8 | 504.7 | 541 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.long-term-investments | 42.28 | 8.8 | 17.3 | 25.9 | ||||||||||||||
balance-sheet.row.tax-assets | 3.67 | 1 | 1 | 0.7 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 53.66 | 12.2 | 9.1 | 8.3 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 2617.6 | 658.6 | 689.1 | 710.2 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.account-payables | 59.55 | 15.5 | 17.2 | 15.4 | ||||||||||||||
balance-sheet.row.short-term-debt | 774.46 | 205.3 | 0.3 | 55.7 | ||||||||||||||
balance-sheet.row.tax-payables | 23.85 | 12.8 | 7.2 | 6.3 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 167 | 167 | ||||||||||||||
Deferred Revenue Non Current | 30.41 | 7.6 | 8.9 | 10.3 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 12.16 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 144.47 | 73.6 | 1.8 | 1.5 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 42.56 | 10.7 | 179.4 | 180 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 1235.79 | 330.1 | 287.8 | 309.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 1662.29 | 414.7 | 412 | 405 | ||||||||||||||
balance-sheet.row.retained-earnings | -1173.2 | -296.2 | -305.2 | -284.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1000.92 | 87.2 | 82.2 | 86 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 600.88 | 307.9 | 292.9 | 286.5 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 2090.9 | 513.5 | 481.8 | 492.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.minority-interest | 239.74 | 67.4 | 84.9 | 105.4 | ||||||||||||||
balance-sheet.row.total-equity | 2330.63 | 580.9 | 566.8 | 598.3 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3566.42 | - | - | - | ||||||||||||||
Total Investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.total-debt | 774.46 | 205.3 | 167.3 | 222.7 | ||||||||||||||
balance-sheet.row.net-debt | 709.27 | 193.1 | 145.6 | 216.9 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 16.06 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 5.29 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 8.3 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -23.72 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | -13.83 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -9.89 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | -5.52 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -0.08 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 30.81 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -418.83 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 456.59 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 29.47 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -60.74 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -8.7 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 38.34 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -31.1 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.02 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 1.46 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 59.79 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 58.33 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | -0.08 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -39.19 | -7.8 | -8.1 | -62.1 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 259.14 | 274.8 | 320.3 | 269.4 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 77.43 | 88.3 | 81.4 | 60.2 | ||||||||||||||
income-statement-row.row.gross-profit | 181.71 | 186.5 | 238.9 | 209.3 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 14.15 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 14.02 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 210.16 | 215.8 | 282.7 | 264.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 287.59 | 304.1 | 364.1 | 324.8 | ||||||||||||||
income-statement-row.row.interest-income | 0.1 | 0.1 | 0.1 | 0.1 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | -9.92 | 57.5 | 54.3 | 57.1 | ||||||||||||||
income-statement-row.row.ebitda-caps | -22.8 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -12.88 | -24.5 | -42.3 | -53.2 | ||||||||||||||
income-statement-row.row.income-before-tax | -12.93 | -8.9 | -40.4 | -78.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | -8.64 | -0.4 | 0.4 | 1.2 | ||||||||||||||
income-statement-row.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 |
Często zadawane pytania
Ile wynosi Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) aktywów ogółem?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) całkowite aktywa to 911018789.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 100763670.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.701.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -0.095.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.004.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -0.050.
Co to jest Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -8496001.960.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 205303152.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 215787255.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 3712099.000.